Swiss-American multinational pharmaceutical, Novartis AG's drug Vymada or Entresto used for patients with heart failure becomes off-patent in January, 2023 Heart failure is a progressive chronic syndrome characterized by a decrease in the functions of the heart and quality of life. 23 million people are affected by it worldwide, while...